Silence Therapeutics PLC Director/PDMR Shareholding (8322B)
13 October 2020 - 1:49AM
UK Regulatory
TIDMSLN
RNS Number : 8322B
Silence Therapeutics PLC
12 October 2020
Director Dealing
12 October 2020
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN
("Silence" or "the Company"), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announces that, on the 8th
and 9th October 2020, 9,750 Shares were purchased by Iain Ross,
Chairman of the Company, through his self-invested personal pension
(SIPP) at GBP4.10 per share, 1,250 Shares were purchased by David
Lemus, Non-Executive Director of the Company, at GBP4.00 per share,
3,000 Shares were purchased by James Ede-Golightly, Non-Executive
Director of the Company, at GBP4.09 per share, and 4,945 Shares
were purchased by Dr. Giles Campion, Executive Director of the
Company, at GBP4.04 per share.
Following this purchase, Iain Ross is interested in 54,443
ordinary shares (0.07%) of the issued share capital of the Company,
David Lemus is interested in 6,876 ordinary shares (0.01%) of the
issued share capital of the Company, James Ede-Golightly is
interested in 3,000 ordinary shares (0.00%) of the issued share
capital of the Company, and Dr. Giles Campion is interested in
14,945 ordinary shares (0.02%) of the issued share capital of the
Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Iain Ross
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Chairman
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.10 9,750
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 9,750 Ordinary Shares
- Price GBP39,976.00
--------------------------- --------------------------------------------
e) Date of the transaction 8 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name David Lemus
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.00 1,250
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 1,250 Ordinary Shares
- Price GBP5,000.00
--------------------------- --------------------------------------------
e) Date of the transaction 9 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name James Ede-Golightly
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.0875 3,000
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 3,000 Ordinary Shares
- Price GBP12,262.50
--------------------------- --------------------------------------------
e) Date of the transaction 8 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
(PDMR) / person closely associated
a) Name Dr. Giles Campion
--------------------------- --------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position / status Executive Director
--------------------------- --------------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Silence Therapeutics plc
--------------------------- --------------------------------------------
b) LEI 213800SSURRJBX85SQ91
--------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares of 5 pence each in Silence
the financial instrument, Therapeutics plc
type of instrument
Identification
code ISIN for Silence Therapeutics plc Ordinary
Shares:
GB00B9GTXM62
--------------------------- --------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares in Silence
Therapeutics plc
--------------------------- --------------------------------------------
c) Prices(a) and volume(s) Price Volume
GBP4.04 4,945
-------
--------------------------- --------------------------------------------
d) Aggregated information
- Aggregated volume 4,945 Ordinary Shares
- Price GBP19,977.80
--------------------------- --------------------------------------------
e) Date of the transaction 9 October 2020
--------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- --------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR & Corporate Communications
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary technology can be used to
engineer short interfering ribonucleic acids (siRNAs) that bind
specifically to and silence, through the RNAi pathway, almost any
gene in the human genome to which siRNA can be delivered. Silence's
wholly owned product candidates include SLN360 designed to address
the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of
Lipoprotein(a) and SLN124 to address beta-thalassemia and
myelodysplastic syndrome. Silence is also developing a C3 targeting
programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals
to reduce the expression of the C3 protein for the treatment of
complement pathway-mediated diseases. Silence maintains ongoing
research and collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals and Takeda. For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSBDGLSBDGGD
(END) Dow Jones Newswires
October 12, 2020 10:49 ET (14:49 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024
